Advertisement

Fall 57: 73 Jahre, ♂, DM Typ 2, Übergewicht, Apoplex Prävention

  • Jan Gröner
Chapter

Zusammenfassung

Ein 73-jähriger Typ-2-Diabetiker, mit einem HbA1c unter 7 % seit über 15 Jahren und einem Body-Mass-Index von 36, erleidet einen Apoplex. Hätte man dies durch bessere Glukosekontrolle oder Gewichtsreduktion durch Diät oder Medikamente verhindern können? Wurde etwas verpasst?

Literatur

  1. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM) (2012) DEGAM-Leitlinie. Schlaganfall. AWMF-Register 053–011. http://www.awmf.org/leitlinien/detail/ll/053–011.html
  2. Duckworth W et al for the VADT Investigators (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139.  https://doi.org/10.1056/NEJMoa080843CrossRefGoogle Scholar
  3. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ (2009) RECORD Study Team (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373(9681):2125–2135.  https://doi.org/10.1016/S0140-6736(09)60953-3CrossRefGoogle Scholar
  4. Kernan WN et al for the IRIS Trial Investigators (2016) Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374:1321–1331.  https://doi.org/10.1056/NEJMoa1506930CrossRefGoogle Scholar
  5. Marso SP et al. for the LEADER Steering Committee on behalf of the LEADER Trial Investigators (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322.  https://doi.org/10.1056/nejmoa1603827CrossRefGoogle Scholar
  6. Nordström P, Pedersen NL, Gustafson Y, Michaëlsson K, Nordström A (2016) Risks of myocardial infarction, death, and diabetes in identical twin pairs with different body mass indexes. JAMA Intern Med 176(10):1522–1529.  https://doi.org/10.1001/jamainternmed.2016.4104 PMID: 27479111CrossRefPubMedGoogle Scholar
  7. Shinton R, Sagar G, Beevers G (1995) Body fat and stroke. Unmasking the hazards of overweight and obesity. J Epidemiol Community Health 49(3):259–264.  https://doi.org/10.1136/jech.49.3.259 PMID: 7629460CrossRefPubMedPubMedCentralGoogle Scholar
  8. The ACCORD Study Group (Action to Control Cardiovascular Risk in Diabetes Study Group) (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559.  https://doi.org/10.1056/NEJMoa0802743CrossRefGoogle Scholar
  9. The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572.  https://doi.org/10.1056/NEJMoa0802987CrossRefGoogle Scholar
  10. The Look AHEAD Research Group (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145–154.  https://doi.org/10.1056/NEJMoa1212914CrossRefPubMedCentralGoogle Scholar
  11. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (9131): 854–865. PMID: 9742977. (Erratum in Lancet 352 (9139):1558)Google Scholar
  12. UK Prospective Diabetes Study (UKPDS) Group (1999) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (9131):837–853. (PMID: 9742976. Erratum in Lancet 354 (9178):602)Google Scholar
  13. UK Prospective Diabetes Study (UKPDS) Group (2008) The action to control cardiovascular risk in diabetes study group. effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559.  https://doi.org/10.1056/NEJMoa0802743CrossRefGoogle Scholar
  14. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J, PROactive Investigators (2007) Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38(3):865–873CrossRefGoogle Scholar
  15. Zhou BF (2002) Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut-off points ofbody mass index and waist circumference in Chinese adults. Biomed Environ Sci 15(1):83–96 PMID: 12046553PubMedGoogle Scholar
  16. Zinman B et al for the EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128.  https://doi.org/10.1056/NEJMoa1504720CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung Innere Medizin IMedizinische UniversitätsklinikHeidelbergDeutschland

Personalised recommendations